Merck has received significant regulatory approvals for its cancer therapy Keytruda, with the US FDA approving a new subcutaneous version designed for both adult and pediatric patients with solid tumors. This innovation aims to simplify administration, potentially extending the life of this top-selling drug. Additionally, Merck has gained positive feedback from European regulators, securing recommendations for the injectable version of Keytruda and new indications, including use in earlier-stage head and neck cancer. The company also received endorsements for ENFLONSIA™, a treatment aimed at preventing respiratory syncytial virus (RSV) in infants. These developments mark a notable step in enhancing cancer treatment options and improving accessibility for patients.